INTS13 and cervical cancer: As shown, silencing of INTS13 in primary pCCa-1 cervical cancer cells, achieved through the application of three distinct shRNAs (shINTS13-Sq1, shINTS13-Sq2, and shINTS13-Sq3, see Fig. 4), elicited a statistically significant augmentation in the enzymatic activities of both Caspase-3 (Fig. 5A) and Caspase-9 (Fig. 5B), relative to parental control (Ctrl) or non-targeting shRNA (shC) groups.